Results 61 to 70 of about 24,471 (215)

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series

Human Vaccines & Immunotherapeutics, 2023
To explore the impact on timely series completion of initiating the HPV vaccine series prior to other vaccines in the adolescent platform (Tdap or meningococcal vacccines), we created a cohort of children aged 9 in 2015 who were continuously enrolled ...
Sidika Kajtezovic, Jake R. Morgan, Stephen Fiascone, Heather M. Brandt, Rebecca B. Perkins   +4 more
doaj   +1 more source

Sutimlimab in Patients With Cold Agglutinin Disease (CAD): Results From a Managed Access Program

European Journal of Haematology, Volume 116, Issue 4, Page 409-415, April 2026.
ABSTRACT Cold agglutinin disease (CAD) is a low‐grade lymphoproliferative disorder accounting for 15%–30% of patients suffering from autoimmune hemolytic anemias. The clonal B cells produce autoantibodies primarily of the IgM‐κ class that cause agglutination of red blood cells (RBCs) at temperatures ≤ 37°C and activate the classical complement pathway ...
Sandra Maria Frey, Pauline Halberstadt, Ferras Alashkar, Veronika Lenz, H. Christian Reinhardt, Alexander Röth   +5 more
wiley   +1 more source

PREVENTION OF MENINGOCOCCAL INFECTION

Медицинский совет, 2017
The article presents data on the relevance of meningococcal infection and the possibility of its prevention by vaccination. Spend a literary analysis of the efficacy and safety of vaccines against meningococcal disease. The results of the epidemiological
I. V. FRIDMAN, S. M. KHARIT
doaj   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2

Биопрепараты: Профилактика, диагностика, лечение, 2018
The present article describes clinical signs of meningococcal disease. It justifies the necessity of its vaccine prevention. The article provides with the historical data on the evolution of inoculants from corpuscular inactivated vaccines to modern ...
M. V. Abramtseva, A. P. Tarasov, T. I. Nemirovskaya   +2 more
doaj  

Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

European Journal of Neurology, Volume 33, Issue 4, April 2026.
C5‐inhibition may represent an effective adjunctive treatment in therapy‐refractory myasthenic crisis, including thymoma‐associated MG (TAMG). ABSTRACT Introduction Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation.
Lea Gerischer, Maike Stein, Alice Schneider, Hanna Tangen, Johanna Loris, Stefanie Glaubitz, Jana Zschüntzsch, Ulrich Hofstadt‐van Oy, Charlotte Schubert, Christoph Heesen, Melina Schlag, Tim Hagenacker, Menekse Oeztuerk, Tobias Ruck, Paolo Doksani, Carla Dusemund, Meret Herdick, Julia Herzig‐Nichtweiß, Philipp Mergenthaler, Frauke Stascheit, Amani Suboh, Lisa Schwarz, Sarah Hoffmann, Andreas Meisel, Sophie Lehnerer   +24 more
wiley   +1 more source

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. [PDF]

, 2018
BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt.
Cohen, Ted, Colijn, Caroline, Colombini, Anaïs, Kristiansen, Paul A, LaForce, F Marc, Resch, Stephen, Trotter, Caroline, Yaesoubi, Maziar, Yaesoubi, Reza   +8 more
core   +3 more sources

Impact of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial [PDF]

, 2014
Background: Meningococcal conjugate vaccines protect individuals directly, but also confer herd protection by interrupting carriage transmission.
Baxter, David, Bazaz, Rohit, Borrow, Ray, Chadwick, David R, Dull, Peter M, Faust, Saul N, Finn, Adam, Ganguli, Amitava, Gilchrist, Stefanie, Gordon, Stephen, Gray, Steve J, Havelock, Tom, Heath, Paul T, Lewis, David J M, Maiden, Martin C J, McCarthy, Maggie, Morales-Aza, Begonia, Neal, Keith R, Okike, Ifeanyichukwu O, Patel, Kamlesh, Pollard, Andrew J, Read, Robert C, Snape, Matthew D, Toneatto, Daniela, Turner, David P J, Wang, Huajun, Williams, John   +26 more
core   +3 more sources